## ES: Eversource Energy (D/B/A) - XLU: Utilities

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($64.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Eversource Customers Could See Small Drop in Electric Bills Early in 2026**
- Source: My Keene Now | 20251217T160149 | Somewhat-Bullish | Relevance: 100%
- Eversource customers in New Hampshire are projected to see a slight decrease in their electric bills during January and February 2026, primarily due to reduced delivery rates. While energy supply costs are expected to remain stable, an average overall bill reduction of about 1-2% is anticipated for typical usage. Eversource encourages customers to explore assistance programs and alternative suppliers.

**2. Eversource Energy (ES) Analyst Rating Update: UBS Lowers Price T**
- Source: GuruFocus | 20251217T195045 | Somewhat-Bearish | Relevance: 96%
- UBS has reiterated a Neutral rating on Eversource Energy (ES) but decreased its price target from $78.00 to $73.00, reflecting a 6.41% reduction in the expected stock value. This adjustment by UBS analyst William Appicelli aligns with evolving market conditions and the company's performance metrics. Other recent analyst actions have included both upgrades and downgrades, with price target changes indicating varying market outlooks for Eversource Energy, a diversified utility company operating in the Northeast US.

**3. 2 Dividend Stocks to Buy for 2026 and Beyond**
- Source: Finviz | 20251218T125550 | Neutral | Relevance: 64%
- This article recommends CVS Health and Abbott Laboratories as two strong dividend stocks for long-term investment, particularly for 2026 and beyond. CVS Health is showing signs of a rebound with strategic initiatives to improve margins, while Abbott Laboratories, a Dividend King, benefits from a diverse product portfolio and recent acquisitions like Exact Sciences. Both companies are highlighted for their ability to navigate challenges and consistently reward shareholders through dividends.

**4. Pennsylvania power line rebuild aims to cut outages for thousands of customers**
- Source: Stock Titan | 20251217T161048 | Neutral | Relevance: 60%
- FirstEnergy (NYSE: FE) is undertaking an approximately $28 million project to rebuild a 15-mile stretch of the Allentown-Lyons-South Hamburg 69-kV line and upgrade four substations in Lehigh and Berks counties, Pennsylvania. This initiative, part of FirstEnergy's larger $28 billion Energize365 program, aims to enhance electric service reliability, reduce outages, and support regional growth for Met-Ed's 592,000 customers. The project, which began in August 2025, is expected to be completed in November 2027.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 5)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | UBS | $73 | $78 | -6% |
| 2025-12-12 | JP Morgan | $71 | $72 | -1% |
| 2025-11-24 | Janney Montgome | $79 | $0 | 0% |
| 2025-11-20 | Mizuho | $68 | $81 | -16% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | UBS | main | Neutral |
| 2025-12-12 | JP Morgan | main | Underweight |
| 2025-11-24 | Janney Montgome | up | Buy |
| 2025-11-20 | Mizuho | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.57M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+2.5%)
- Blackrock Inc.: 10.9% (+4.3%)
- State Street Corpora: 7.1% (-2.2%)
- FMR, LLC: 2.9% (-1.9%)
- Geode Capital Manage: 2.5% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Forward P/E 13.5x stretched relative to 5% growth. Analyst sentiment negative (5 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 0.77 |
| 52W Range | $52.28 - $75.25 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 13.5 |
| Current P/E | 14.1 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.5% to -0.1% (-3.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). RSI neutral at 44. OFD pattern: -MUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.12% (CS: 51) | Neutral |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 0.955x | Below |
| vs SMA200 | 1.027x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $67.15
- **Stop Loss:** $64.45 (4.0% risk)
- **Target:** $69.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 222
- **Position Value:** $14,907.30
- **Portfolio %:** 14.91%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-11 (Est: $1.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.15 | $1.19 | +3.6% |
| 2025Q2 | $0.95 | $0.96 | +1.0% |
| 2025Q1 | $1.51 | $1.50 | -0.6% |
| 2024Q4 | $0.99 | $1.01 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*